Novoron Bioscience were recently awarded a grant to further their work investigating a potentially novel therapy that can repair damage in multiple sclerosis. In this video, we interview Dr Travis Stiles (CEO/President – Novoron Bioscience) and discuss a wide range of topics, including the potential of their research for people with MS and the challenges faced by a biotechnology company.
With more than 2.3 million people globally fighting the disease, multiple sclerosis (MS) is one of the most common diseases of the brain and spinal cord. MS is an autoimmune disease of the central nervous system where the immune system attacks myelin causing demyelination. Myelin forms a protective covering around nerves, allowing them to rapidly transmit signals to efficiently facilitate vision and coordinate body movement.
Today’s approved MS therapies are aimed at reducing the immune system attack on myelin. On the flip-side of the problem, Novoron is pursuing a novel therapeutic approach to remyelinate. Remyelination is intended to protect the neurons from further damage and maintain function.
Novoron observed that RAP could block Rho activation by inhibiting LRP1 and restore neuronal outgrowth in vitro. LRP1 is an established receptor for myelin debris and contributes to inhibition of remyelination via activation of Rho. Rho and Rho-kinase are well considered targets for multiple sclerosis, but are difficult to effectively inhibit therapeutically. Novoron is testing RAP, which can attenuate Rho activation both in vitro and in vivo and is actively transported across the blood brain barrier in vivo.
Click the link below for additional information: